PGF2α-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN

Prostaglandins and Other Lipid Mediators

Volumn 85, Issue 1-2, 2008, Pages 49-57

  Rice, K M ^a,c,d   Uddemarri, S ^a,d   Desai, D H ^c,d   Morrison, R G ^a   Harris, R ^b,c,d   Wright, G L ^c,d   Blough, E R ^a,c,d  

^a MARSHALL UNIVERSITY   (United States)

^b WEST VIRGINIA STATE UNIVERSITY   (United States)

^c MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Marshall University   (United States)

Author keywords

A7r5; Hypertrophy; p70S6k; PGF2 ; PTEN; VSMC

Indexed keywords

FLUPROSTENOL; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN F2 ALPHA; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; TENSIN; UO 126; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN F; PROTEIN KINASE; PTEN PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MUSCLE HYPERTROPHY; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CONTENT; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOTTING, WESTERN; CELL LINE; DINOPROST; FLUORESCENT ANTIBODY TECHNIQUE; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, FLUORESCENCE; MUSCLE, SMOOTH, VASCULAR; PROSTAGLANDINS F, SYNTHETIC; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; RATS; REACTIVE OXYGEN SPECIES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA;

EID: 38049038824     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.10.009     Document Type: Article

References (50)

1. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 5548 (2001) 1871-1875
2. Abramovitz M., Boie Y., Nguyen T., et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269 4 (1994) 2632-2636
3. Chazov E.I., Pomoinetsky V.D., Geling N.G., Orlova T.R., Nekrasova A.A., and Smirnov V.N. Heart adaptation to acute pressure overload: an involvement of endogenous prostaglandins. Circ Res 45 2 (1979) 205-211
4. Vandenburgh H.H., Hatfaludy S., Sohar I., and Shansky J. Stretch-induced prostaglandins and protein turnover in cultured skeletal muscle. Am J Physiol 259 2 Pt 1 (1990) C232-C240
5. Karmazyn M. Synthesis and relevance of cardiac eicosanoids with particular emphasis on ischemia and reperfusion. Can J Physiol Pharmacol 67 8 (1989) 912-921
6. Mentz P., Pawelski K.E., Giessler C., Mest H.J., Mannes F., and Rotzoll S. Myocardial biosynthesis of prostacyclin and the influence of cardiac loading and drugs. Biomed Biochim Acta 47 10-11 (1988) S244-S247
7. Adams J.W., Migita D.S., Yu M.K., et al. Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 271 2 (1996) 1179-1186
8. Lai J., Jin H., Yang R., et al. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 271 6 Pt 2 (1996) H2197-H2208
9. Kunapuli P., Lawson J.A., Rokach J.A., Meinkoth J.L., and FitzGerald G.A. Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem 273 35 (1998) 22442-22452
10. Dorn II G.W., Becker M.W., and Davis M.G. Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle. J Biol Chem 267 34 (1992) 24897-24905
11. Kentera D., Susic D., and Zdravkovic M. Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. Respiration 37 4 (1979) 192-196
12. McLennan I.S. Hormonal regulation of myoblast proliferation and myotube production in vivo: influence of prostaglandins. J Exp Zool 241 2 (1987) 237-245
13. Templeton G.H., Padalino M., and Moss R. Influences of inactivity and indomethacin on soleus phosphatidylethanolamine and size. Prostaglandins 31 3 (1986) 545-559
14. Katsuyama M., Fan C., and Yabe-Nishimura C. NADPH oxidase is involved in prostaglandin F2alpha-induced hypertrophy of vascular smooth muscle cells: induction of NOX1 by PGF2alpha. J Biol Chem 277 16 (2002) 13438-13442
15. Fukuyama K., Ichiki T., Ono H., et al. cAMP-response element-binding protein mediates prostaglandin F2alpha-induced hypertrophy of vascular smooth muscle cells. Biochem Biophys Res Commun 338 2 (2005) 910-918
16. Rao G.N., Madamanchi N.R., Lele M., et al. A potential role for extracellular signal-regulated kinases in prostaglandin F2alpha-induced protein synthesis in smooth muscle cells. J Biol Chem 274 18 (1999) 12925-12932
17. Lassegue B., Sorescu D., Szocs K., et al. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88 9 (2001) 888-894
18. Haider U.G., Sorescu D., Griendling K.K., Vollmar A.M., and Dirsch V.M. Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol Pharmacol 62 4 (2002) 772-777
19. Takahashi T., Taniguchi T., Konishi H., Kikkawa U., Ishikawa Y., and Yokoyama M. Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol 276 6 Pt 2 (1999) H1927-H1934
20. Blanc A., Pandey N.R., and Srivastava A.K. Synchronous activation of ERK 1/2, p38mapk and PKB/Akt signaling by H2O2 in vascular smooth muscle cells: potential involvement in vascular disease (review). Int J Mol Med 11 2 (2003) 229-234
21. El Jamali A., Freund C., Rechner C., Scheidereit C., Dietz R., and Bergmann M.W. Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3beta. FASEB J 18 10 (2004) 1096-1098
22. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., and Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37 2 (2004) 449-471
23. Hardt S.E., and Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 90 10 (2002) 1055-1063
24. Morinelli T.A., Finley E.L., Jaffa A.A., Kurtz D.T., and Ullian M.E. Tyrosine phosphorylation of phosphatidylinositol 3-kinase and of the thromboxane A2 (TXA2) receptor by the TXA2 mimetic I-BOP in A7r5 cells. Biochem Pharmacol 53 12 (1997) 1823-1832
25. + mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J Pharmacol Exp Ther 304 1 (2003) 238-245
26. Rothe G., and Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescin. J Leukoc Biol 47 5 (1990) 440-448
27. Rice K.M., Desai D.H., Kinnard R.S., Harris R., Wright G.L., and Blough E.R. Load-induced focal adhesion mechanotransduction is altered with aging in the Fischer 344/NNiaHSd × Brown Norway/BiNia rat aorta. Biogerontology (2006)
28. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76 9 (1979) 4350-4354
29. Breyer R.M., Bagdassarian C.K., Myers S.A., and Breyer M.D. Prostanoid receptors: subtypes and signaling. Ann Rev Pharmacol Toxicol 41 (2001) 661-690
30. Saward L., and Zahradka P. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 81 2 (1997) 249-257
31. Jefferies H.B., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., and Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16 12 (1997) 3693-3704
32. Bodine S.C., Stitt T.N., Gonzalez M., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3 11 (2001) 1014-1019
33. Giasson E., and Meloche S. Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J Biol Chem 270 10 (1995) 5225-5231
34. Ono Y., Ito H., Tamamori M., et al. Role and relation of p70 S6 and extracellular signal-regulated kinases in the phenotypic changes of hypertrophy of cardiac myocytes. Jpn Circ J 64 9 (2000) 695-700
35. Takano H., Komuro I., Zou Y., Kudoh S., Yamazaki T., and Yazaki Y. Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes. FEBS Lett 379 3 (1996) 255-259
36. Jung D.K., Bae G.U., Kim Y.K., et al. Hydrogen peroxide mediates arsenite activation of p70(s6k) and extracellular signal-regulated kinase. Exp Cell Res 290 1 (2003) 144-154
37. Ding M., Li J., Leonard S.S., et al. Differential role of hydrogen peroxide in UV-induced signal transduction. Mol Cell Biochem 234-235 1-2 (2002) 81-90
38. Zhang X., Shu L., Hosoi H., Murti K.G., and Houghton P.J. Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem 277 31 (2002) 28127-28134
39. Christophe D., Christophe-Hobertus C., and Pichon B. Nuclear targeting of proteins: how many different signals?. Cell Signal 12 5 (2000) 337-341
40. Rommel C., Bodine S.C., Clarke B.A., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3 11 (2001) 1009-1013
41. Vyas D.R., Spangenburg E.E., Abraha T.W., Childs T.E., and Booth F.W. GSK-3beta negatively regulates skeletal myotube hypertrophy. Am J Physiol Cell Physiol 283 2 (2002) C545-C551
42. Antos C.L., McKinsey T.A., Frey N., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99 2 (2002) 907-912
43. Neal J.W., and Clipstone N.A. Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. J Biol Chem 276 5 (2001) 3666-3673
44. Jefferson L.S., Fabian J.R., and Kimball S.R. Glycogen synthase kinase-3 is the predominant insulin-regulated eukaryotic initiation factor 2B kinase in skeletal muscle. Int J Biochem Cell Biol 31 1 (1999) 191-200
45. Welsh G.I., Miller C.M., Loughlin A.J., Price N.T., and Proud C.G. Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 421 2 (1998) 125-130
46. Liu Z., Dronadula N., and Rao G.N. A novel role for nuclear factor of activated T cells in receptor tyrosine kinase and G protein-coupled receptor agonist-induced vascular smooth muscle cell motility. J Biol Chem 279 39 (2004) 41218-41226
47. Yamada K.M., and Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114 Pt 13 (2001) 2375-2382
48. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., and Yamada K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280 5369 (1998) 1614-1617
49. 2. J Biol Chem 277 23 (2002) 20336-20342
50. Torres J., and Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276 2 (2001) 993-998